136 related articles for article (PubMed ID: 23257396)
1. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
2. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
3. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine.
Damaso CR; Esposito JJ; Condit RC; Moussatché N
Virology; 2000 Nov; 277(2):439-49. PubMed ID: 11080491
[TBL] [Abstract][Full Text] [Related]
4. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
5. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270
[TBL] [Abstract][Full Text] [Related]
6. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
Duraffour S; Vigne S; Vermeire K; Garcel A; Vanstreels E; Daelemans D; Yang G; Jordan R; Hruby DE; Crance JM; Garin D; Andrei G; Snoeck R
Antivir Ther; 2008; 13(8):977-90. PubMed ID: 19195323
[TBL] [Abstract][Full Text] [Related]
8. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.
Duraffour S; Lorenzo MM; Zöller G; Topalis D; Grosenbach D; Hruby DE; Andrei G; Blasco R; Meyer H; Snoeck R
J Antimicrob Chemother; 2015 May; 70(5):1367-80. PubMed ID: 25630650
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades.
Pires MA; Rodrigues NFS; de Oliveira DB; de Assis FL; Costa GB; Kroon EG; Mota BEF
Antiviral Res; 2018 Apr; 152():36-44. PubMed ID: 29427676
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice.
Quenelle DC; Buller RM; Parker S; Keith KA; Hruby DE; Jordan R; Kern ER
Antimicrob Agents Chemother; 2007 Feb; 51(2):689-95. PubMed ID: 17116683
[TBL] [Abstract][Full Text] [Related]
11. Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.
Grosenbach DW; Hruby DE
Methods Mol Biol; 2019; 2023():143-155. PubMed ID: 31240676
[TBL] [Abstract][Full Text] [Related]
12. FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture.
Reis SA; Moussatché N; Damaso CR
J Appl Microbiol; 2006 Jun; 100(6):1373-80. PubMed ID: 16696686
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC.
Jesus DM; Moussatché N; Damaso CR
Int J Antimicrob Agents; 2009 Jan; 33(1):75-9. PubMed ID: 18804965
[TBL] [Abstract][Full Text] [Related]
14. (+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents.
Sokolova AS; Kovaleva KS; Yarovaya OI; Bormotov NI; Shishkina LN; Serova OA; Sergeev AA; Agafonov AP; Maksuytov RA; Salakhutdinov NF
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2100038. PubMed ID: 33605479
[TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.
Medaglia ML; Moussatché N; Nitsche A; Dabrowski PW; Li Y; Damon IK; Lucas CG; Arruda LB; Damaso CR
J Virol; 2015 Dec; 89(23):11909-25. PubMed ID: 26378174
[TBL] [Abstract][Full Text] [Related]
16. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
Smee DF
Antivir Chem Chemother; 2008; 19(3):115-24. PubMed ID: 19024628
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.
Grosenbach DW; Berhanu A; King DS; Mosier S; Jones KF; Jordan RA; Bolken TC; Hruby DE
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):838-43. PubMed ID: 20080762
[TBL] [Abstract][Full Text] [Related]
18. A multiplex PCR for viruses associated with exanthematic and vesicular disease in cattle.
Cargnelutti JF; Weiblen R; Flores EF
J Virol Methods; 2017 Jan; 239():38-41. PubMed ID: 27793645
[TBL] [Abstract][Full Text] [Related]
19. A PCR-based assay for detection of emerging vaccinia-like viruses isolated in Brazil.
Damaso CR; Reis SA; Jesus DM; Lima PS; Moussatché N
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):39-46. PubMed ID: 16949244
[TBL] [Abstract][Full Text] [Related]
20. SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral.
Pereira AC; Soares-Martins JA; Leite FG; Da Cruz AF; Torres AA; Souto-Padrón T; Kroon EG; Ferreira PC; Bonjardim CA
Antiviral Res; 2012 Jan; 93(1):69-77. PubMed ID: 22068148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
